According to regulatory findings, the facility conditions cited by the FDA were described as not in compliance with established standards. While the lawsuit referenced these concerns as part of its claims, Colgate-Palmolive denied all allegations. The company stated it agreed to settle the case to avoid the expense and uncertainty associated with prolonged litigation and to maintain focus on its operations and customers.
The proposed settlement has received preliminary court approval. Under its terms, eligible consumers may file a claim for reimbursement. Those who submit claims without proof of purchase could receive compensation comparable to the average retail price of the product. Consumers who provide valid proof of purchase may qualify for a full refund, limited to up to three products per household. Only one claim is permitted per household.
Claims can be submitted online through the official settlement website or by mailing a completed form to the designated class administrator in Portland, Oregon. Consumers seeking clarification about eligibility may contact the settlement administrator via email.
To qualify for compensation, claims must be submitted online or postmarked by Sunday, July 6, 2026. A final approval hearing for the settlement is scheduled for 10:00 AM CT on Wednesday, September 10, 2026, in the United States District Court for the Eastern District of New York. The outcome of that hearing will determine whether payments will be issued to approved claimants.
